InMed Pharmaceuticals Inc. (INM)
Automate Your Wheel Strategy on INM
With Tiblio's Option Bot, you can configure your own wheel strategy including INM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INM
- Rev/Share 5.0717
- Book/Share 13.8227
- PB 0.1194
- Debt/Equity 0.0552
- CurrentRatio 6.9939
- ROIC -0.5422
- MktCap 2986378.0
- FreeCF/Share -5.8411
- PFCF -0.5239
- PE -0.197
- Debt/Assets 0.0476
- DivYield 0
- ROE -0.932
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Published: November 18, 2025 by: Newsfile Corp
Sentiment: Neutral
Data demonstrate a favorable bioavailability profile of INM-901 oral formulation Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today announced the successful completion of pharmacokinetic ("PK") studies in large animal models for its Alzheimer's disease candidate INM-901. This marks the first preclinical study in which the oral formulation of INM-901 was administered in …
Read More
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025
Published: September 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Eric A. Adams, InMed's CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025.
Read More
About InMed Pharmaceuticals Inc. (INM)
- IPO Date 2014-05-05
- Website https://www.inmedpharma.com
- Industry Biotechnology
- CEO Eric A. Adams Chem., M.I.B.
- Employees 13